Sex and Gender Omic Biomarkers in Men and Women With COPD: Considerations for Precision Medicine.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 33745988.
- Also identified by DOI 10.1016/j.chest.2021.03.024 and PMC identifier 8295903.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Sex and gender differences in lung health and disease are imperative to consider and study if precision pulmonary medicine is to be achieved. The development of reliable COPD biomarkers has been elusive, and the translation of biomarkers to clinical care has been limited. Useful and effective biomarkers must be developed with attention to clinical heterogeneity of COPD; inherent heterogeneity exists related to grouping women and men together in the studies of COPD. Considering sex and gender differences and influences related to -omics may represent progress in susceptibility, diagnostic, prognostic, and therapeutic biomarker development and clinical innovation to improve the lung health of men and women.
Medical subject headings
- Biomarkers
- Lung
- Precision Medicine
- Pulmonary Disease, Chronic Obstructive